Classifying patients for breast cancer by detection of autoantibodies against a panel of conformation-carrying antigens

Cancer Prevention Research

Volumn 7, Issue 5, 2014, Pages 545-555

  Evans, Rick L ^a   Pottala, James V ^b   Egland, Kristi A ^a,b  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; AUTOANTIBODY; DICKKOPF 1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; ESTROGEN RECEPTOR; MEMBRANE PROTEIN; MUCIN 1; PROTEIN ANGPTL4; PROTEIN GAL1; PROTEIN GFRA1; PROTEIN GRN; PROTEIN LRRC15; UNCLASSIFIED DRUG; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DNA LIBRARY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EUKARYOTE; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUMOR GENE; TUMOR INVASION; TUMOR VOLUME; ADENOCARCINOMA IN SITU; AGED; BLOOD; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE CONTROL STUDY; CELL LINE; CHEMISTRY; CLASSIFICATION; EMERGENCY HEALTH SERVICE; HEK293 CELL LINE; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROTEIN CONFORMATION;

ADENOCARCINOMA IN SITU; AGED; ANTIGENS, NEOPLASM; AUTOANTIBODIES; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; CELL LINE; EARLY DETECTION OF CANCER; EPITOPES; FEMALE; HEK293 CELLS; HUMANS; MIDDLE AGED; PROTEIN CONFORMATION; RECEPTOR, ERBB-2; TRIAGE; TUMOR MARKERS, BIOLOGICAL;

EID: 84900820911     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0416     Document Type: Article

References (47)

1. National Cancer Institute at the National Institutes of Health 2012 [updated 07/24/2012; cited 2013]. Available from: http://www.cancer.gov/ cancertopics/factsheet/detection/mammograms.
2. Breastcancer.org, mammography: benefits, risks, what you need to know 2013. Available from: http://www.breastcancer.org/symptoms/testing/types/ mammograms/bene fits-risks.jsp.
3. American Cancer Society, Find Support & Treatment, Mammograms and Other Breast Imaging Procedures 2012. Available from: http://www.cancer.org/ Treatment/UnderstandingYourDiagnosis/ExamsandTestDescriptions/ MammogramsandOtherBreastImagingProcedures/mammograms-and-other-breast-imaging- procedures-having-a-mammogram.
4. Agnantis NJ, Goussia AC, Stefanou D. Tumor markers: an update approach for their prognostic significance. Part I. In Vivo 2003;17:609-18. (Pubitemid 38165463)
5. Arciero C, Somiari SB, Shriver CD, Brzeski H, Jordan R, Hu H, et al. Functional relationship and gene ontology classification of breast cancer biomarkers. Int J Biol Markers 2003;18:241-72. (Pubitemid 38219723)
6. Bernoux A, de Cremoux P, Laine-Bidron C, Martin EC, Asselain B, Magdelenat H. Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Institut Curie Breast Cancer Study Group. Breast Cancer Res Treat 1998;49:219-25. (Pubitemid 28416787)
7. Dowsett M, Cooke T, Ellis I, Gullick WJ, Gusterson B, Mallon E, et al. Assessment of HER2 status in breast cancer: why, when and how? Eur J Cancer 2000;36:170-6. (Pubitemid 30102192)
8. Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol 1999;26(4 Suppl 12):71-7. (Pubitemid 29411435)
9. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82. (Pubitemid 17231334)
10. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12. (Pubitemid 19147683)
11. Kaklamani V. A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX. Expert Rev Mol Diagn 2006;6:803-9. (Pubitemid 44911030)
12. Manjili MH, Najarian K, Wang XY. Signatures of tumor-immune interactions as biomarkers for breast cancer prognosis. Future Oncol 2012;8:703-11.
13. Reuschenbach M, von Knebel Doeberitz M, Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 2009;58:1535-44.
14. Casiano CA, Mediavilla-Varela M, Tan EM. Tumor-associated antigen arrays for the serological diagnosis of cancer. Mol Cell Proteomics 2006;5:1745-59. (Pubitemid 44688185)
15. Lu H, Goodell V, Disis ML. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 2008;7:1388-94.
16. Desmetz C, Mange A, Maudelonde T, Solassol J. Autoantibody signatures: progress and perspectives for early cancer detection. J Cell Mol Med 2011;15:2013-24.
17. Piura E, Piura B. Autoantibodies to tailor-made panels of tumor-associated antigens in breast carcinoma. J Oncol 2011;2011:982425.
18. Piura E, Piura B. Autoantibodies to tumor-associated antigens in breast carcinoma. J Oncol 2010;2010:264926.
19. Finn OJ. Immune response as a biomarker for cancer detection and a lot more. N Engl J Med 2005;353:1288-90. (Pubitemid 41345953)
20. Pavoni E, Pucci A, Vaccaro P, Monteriu G, Ceratti Ade P, Lugini A, et al. A study of the humoral immune response of breast cancer patients to a panel of human tumor antigens identified by phage display. Cancer Detect Prev 2006;30:248-56. (Pubitemid 44163059)
21. Sioud M, Hansen MH. Profiling the immune response in patients with breast cancer by phage-displayed cDNA libraries. Eur J Immunol 2001;31:716-25. (Pubitemid 32237107)
22. Storr SJ, Chakrabarti J, Barnes A, Murray A, Chapman CJ, Robertson JF. Use of autoantibodies in breast cancer screening and diagnosis. Expert Rev Anticancer Ther 2006;6:1215-23. (Pubitemid 44304689)
23. Tan EM, Shi FD. Relative paradigms between autoantibodies in lupus and autoantibodies in cancer. Clin Exp Immunol 2003;134:169-77. (Pubitemid 37372266)
24. Barlow DJ, Edwards MS, Thornton JM. Continuous and discontinuous protein antigenic determinants. Nature 1986;322:747-8. (Pubitemid 16074126)
25. Laver WG, Air GM, Webster RG, Smith-Gill SJ. Epitopes on protein antigens: misconceptions and realities. Cell 1990;61:553-6.
26. Ramachandran N, Hainsworth E, Bhullar B, Eisenstein S, Rosen B, Lau AY, et al. Self-assembling protein microarrays. Science 2004;305:86-90. (Pubitemid 38869377)
27. Ehrlich JR, Qin S, Liu BC. The 'reverse capture' autoantibody microarray: a native antigen-based platform for autoantibody profiling. Nat Protoc 2006;1:452-60.
28. Tan HT, Low J, Lim SG, Chung MC. Serum autoantibodies as biomarkers for early cancer detection. FEBS J 2009;276:6880-904.
29. Egland KA, Vincent JJ, Strausberg R, Lee B, Pastan I. Discovery of the breast cancer gene BASE using a molecular approach to enrich for genes encoding membrane and secreted proteins. Proc Natl Acad Sci U S A 2003;100:1099-104. (Pubitemid 36183962)
30. Boyle JS, Koniaras C, Lew AM. Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization. Int Immunol 1997;9:1897-906. (Pubitemid 28005827)
31. Drew DR, Lightowlers M, Strugnell RA. Humoral immune responses to DNA vaccines expressing secreted, membrane bound and non-secreted forms of the Tania ovis 45W antigen. Vaccine 2000;18:2522-32. (Pubitemid 30207037)
32. Bendtsen JD, Nielsen H, von Heijne G, Brunak S. Improved prediction of signal peptides: SignalP 3.0. J Mol Biol 2004;340:783-95. (Pubitemid 38829638)
33. Nielsen H, Engelbrecht J, Brunak S, von Heijne G. Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Protein Eng 1997;10:1-6.
34. Krogh A, Larsson B, von Heijne G, Sonnhammer EL. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol 2001;305:567-80. (Pubitemid 33032862)
35. Bergstralh EJ, Kosanke JL. Computerized matching of cases to controls. Rochester, MN: Mayo Clinic Department of Health Science Research, 1995.
36. Hosmer DW, Lemeshow S. Goodness of fit tests for the multiple logistic regression model. Communications in Statistics - Theory and Methods: Taylor & Francis Group; 1980. p. 1043-69.
37. Akaike H. Information theory and an extension of the maximum likelihood principle. In:Kotz S, Johnson NL, editors. Breakthroughs in Statistics. Springer Series in Statistics: Springer New York; 1992. p. 610-24.
38. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27. (Pubitemid 44854747)
39. Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994;54:2856-60. (Pubitemid 24187762)
40. von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, Verstraeten AA, Litvinov SV, van Kamp GJ, et al. Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. Eur J Cancer 1996;32A:1325-31. (Pubitemid 26246705)
41. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997;15:3363-7. (Pubitemid 27485856)
42. Ladd JJ, Chao T, Johnson MM, Qiu J, Chin A, Israel R, et al. Autoantibody signatures involving glycolysis and splicesome proteins precede a diagnosis of breast cancer among postmenopausal women. Cancer Res 2013;73:1502-13.
43. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
44. Lacombe J, Mange A, Jarlier M, Bascoul-Mollevi C, Rouanet P, Lamy PJ, et al. Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers. Int J Cancer 2013;132:1105-13.
45. Mange A, Lacombe J, Bascoul-Mollevi C, Jarlier M, Lamy PJ, Rouanet P, et al. Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer. Clin Cancer Res 2012;18:1992-2000.
46. Ye H, Sun C, Ren P, Dai L, Peng B, Wang K, et al. Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer. Oncol Lett 2013;5:663-8.
47. Gion M, Mione R, Leon AE, Dittadi R. Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer. Clin Chem 1999;45:630-7. (Pubitemid 29220324)